BMC cancer · 2026
Integrin-binding sialoprotein as an extracellular matrix-associated independent prognostic biomarker in glioma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Wei-Wei, Hao Yu-Xing, Hong Wen-Qing, Yuan Qi-You, Jin Hao-Dong, Peng Jin, Shan Ming, Li Cheng-Cong
Аннотация
BACKGROUND: Integrin-binding sialoprotein (IBSP) has been implicated in bone metastasis in breast, lung, and prostate cancers. However, its role in glioma remains insufficiently characterized. The aim of this study was to assess the expression profile and prognostic significance of IBSP in patients with glioma.
METHODS: Gene expression data associated with glioma prognosis were obtained from the Chinese Glioma Genome Atlas and Gene Expression Omnibus Series databases and analyzed in relation to clinical characteristics. The prognostic value of IBSP was assessed using univariate and multivariate Cox regression analyses. Immunohistochemical analysis was performed to validate these findings. Gene set enrichment analysis (GSEA) was conducted to identify molecular pathways associated with IBSP expression and its contribution to adverse prognosis. Additionally, gene set cancer analysis was used to explore potential therapeutic agents targeting IBSP.
RESULTS: IBSP expression was elevated in glioma tissues and demonstrated a positive correlation with increasing World Health Organization grade. Multivariate Cox regression analysis identified IBSP as an independent prognostic factor across multiple datasets (HR = 1.531; 95% CI: 1.07-2.192; p = 0.020). GSEA indicated that IBSP is involved in apoptosis, coagulation, and complement pathways. Several genes, including CASP4, KYNU, MSR1, PLAUR, SIGLEC9, and SLC16A3, were positively correlated with IBSP expression and are implicated in glioma pathogenesis. Furthermore, alvocidib and dinaciclib were identified as potential therapeutic agents targeting IBSP.
CONCLUSIONS: IBSP represents an independent prognostic biomarker associated with adverse outcomes in glioma. These findings provide insight into the molecular mechanisms underlying IBSP-associated glioma progression and highlight potential therapeutic targets that may contribute to improved clinical outcomes in patients with glioma.
METHODS: Gene expression data associated with glioma prognosis were obtained from the Chinese Glioma Genome Atlas and Gene Expression Omnibus Series databases and analyzed in relation to clinical characteristics. The prognostic value of IBSP was assessed using univariate and multivariate Cox regression analyses. Immunohistochemical analysis was performed to validate these findings. Gene set enrichment analysis (GSEA) was conducted to identify molecular pathways associated with IBSP expression and its contribution to adverse prognosis. Additionally, gene set cancer analysis was used to explore potential therapeutic agents targeting IBSP.
RESULTS: IBSP expression was elevated in glioma tissues and demonstrated a positive correlation with increasing World Health Organization grade. Multivariate Cox regression analysis identified IBSP as an independent prognostic factor across multiple datasets (HR = 1.531; 95% CI: 1.07-2.192; p = 0.020). GSEA indicated that IBSP is involved in apoptosis, coagulation, and complement pathways. Several genes, including CASP4, KYNU, MSR1, PLAUR, SIGLEC9, and SLC16A3, were positively correlated with IBSP expression and are implicated in glioma pathogenesis. Furthermore, alvocidib and dinaciclib were identified as potential therapeutic agents targeting IBSP.
CONCLUSIONS: IBSP represents an independent prognostic biomarker associated with adverse outcomes in glioma. These findings provide insight into the molecular mechanisms underlying IBSP-associated glioma progression and highlight potential therapeutic targets that may contribute to improved clinical outcomes in patients with glioma.